Potentiation of the cell growth inhibitory effect of beta interferon by mopidamole.
It was suggested that the antitumor effect of the interferons is based in part on their ability to stimulate increased cAMP production. We have explored the interaction of human fibroblastic beta interferon (HFIF) with a cAMP decomposition inhibitory pyrimido-pyrimidine derivative, Mopidamole (RA-233) in cultures of neoplastic and normal cell lines. Mopidamole potentiated the growth inhibitory effect of HFIF in cultures of ES-1 malignant melanoma cells, LNCaP prostatic carcinoma cells, RT-4 transitional carcinoma cells, HT-29 colon adenocarcinoma cells and in diploid fibroblast cells.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004357:Drug Synergism; D005347:Fibroblasts / Q000166:cytology; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D009012:Mopidamol / Q000494:pharmacology*; D009369:Neoplasms / Q000473:pathology*; D011743:Pyrimidines / Q000494:pharmacology*
D007370:Interferon Type I; D011743:Pyrimidines; D009012:Mopidamol; D015105:3',5'-Cyclic-AMP Phosphodiesterases